Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,437,302
  • Shares Outstanding, K 181,830
  • Annual Sales, $ 1,860 M
  • Annual Income, $ 859,100 K
  • 60-Month Beta 0.59
  • Price/Sales 7.70
  • Price/Cash Flow 62.65
  • Price/Book 3.46
Trade BMRN with:

Options Overview

Details
  • Implied Volatility 34.27%
  • Historical Volatility 19.16%
  • IV Percentile 4%
  • IV Rank 6.76%
  • IV High 74.43% on 01/08/21
  • IV Low 31.36% on 03/22/21
  • Put/Call Vol Ratio 0.41
  • Today's Volume 3,452
  • Volume Avg (30-Day) 1,892
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 71,905
  • Open Int (30-Day) 43,307

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.06
  • Number of Estimates 6
  • High Estimate 0.17
  • Low Estimate -0.06
  • Prior Year 0.38
  • Growth Rate Est. (year over year) -84.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.77 +9.11%
on 03/25/21
79.85 -0.56%
on 04/07/21
+2.19 (+2.84%)
since 03/16/21
3-Month
72.77 +9.11%
on 03/25/21
89.13 -10.92%
on 01/25/21
-3.57 (-4.30%)
since 01/15/21
52-Week
71.35 +11.28%
on 09/11/20
131.95 -39.82%
on 07/21/20
-5.82 (-6.83%)
since 04/16/20

Most Recent Stories

More News
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on...

BMRN : 79.40 (+0.80%)
Rectangle Pattern Suggests a Momentous Move in BioMarin Pharmaceutical Stock Soon

A rectangle pattern has formed in the chart of BioMarin Pharmaceutical Inc. (BMRN). When this pattern is broken, a breakout or breakdown could soon occur. Read more to learn how to take advantage of this...

BMRN : 79.40 (+0.80%)
BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BMRN : 79.40 (+0.80%)
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an...

BMRN : 79.40 (+0.80%)
BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into BioMarin Pharmaceutical...

BMRN : 79.40 (+0.80%)
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag

FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.

RHHBY : 42.1100 (+0.62%)
PFE : 38.57 (+2.58%)
BMRN : 79.40 (+0.80%)
SGMO : 11.48 (-2.46%)
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene...

BMRN : 79.40 (+0.80%)
BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an...

BMRN : 79.40 (+0.80%)
Stocks Can't Follow Through on Recent Rally

Stocks Can't Follow Through on Recent Rally

ARLO : 6.25 (+5.04%)
FLDM : 4.63 (-1.49%)
TACO : 10.61 (+0.76%)
MNRL : 15.86 (-1.61%)
VSAT : 49.08 (+2.89%)
BMRN : 79.40 (+0.80%)
JNJ : 162.24 (+1.15%)
TGT : 208.55 (+1.36%)
FB : 306.18 (-0.53%)
AAPL : 134.16 (-0.25%)
AMZN : 3,399.44 (+0.60%)
MSFT : 260.74 (+0.48%)
TSLA : 739.78 (+0.13%)
BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull

BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.

SNY : 51.30 (+1.20%)
BMRN : 79.40 (+0.80%)
ACOR : 4.19 (+6.62%)
MRNA : 170.81 (+6.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment...

See More

Key Turning Points

3rd Resistance Point 81.51
2nd Resistance Point 80.55
1st Resistance Point 79.98
Last Price 79.40
1st Support Level 78.45
2nd Support Level 77.49
3rd Support Level 76.92

See More

52-Week High 131.95
Fibonacci 61.8% 108.80
Fibonacci 50% 101.65
Fibonacci 38.2% 94.50
Last Price 79.40
52-Week Low 71.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar